Navigation Links
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Date:7/12/2011

IL-6 inhibition.  The incidence of serious adverse events among the five sarilumab treatment groups and placebo group were comparable.

Sarilumab also demonstrated significant benefit compared to placebo in secondary endpoints, including ACR 50, ACR 70, and DAS 28 scores, additional measures of clinical activity used in RA trials.  

"Following these encouraging Phase 2b results in rheumatoid arthritis, the companies are currently discussing the dose(s) of sarilumab to advance into the Phase 3 portion of the MOBILITY  trial," said Elias Zerhouni, President, Global Research & Development, Sanofi.

"The MOBILITY results provide evidence that IL-6R blockade with sarilumab represents a promising new anti-inflammatory investigational therapy for reducing RA disease symptoms.  We are very pleased that the first of our novel VelocImmune® derived antibodies is poised to enter Phase 3 development," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Research Laboratories.

In the Phase 2b ALIGN trial in ankylosing spondylitis (AS), sarilumab did not demonstrate significant and clinically meaningful improvements in signs and symptoms of active AS compared to placebo in patients who had inadequate response to NSAIDs.  Sarilumab was generally well tolerated. The most common adverse events reported more frequently in active treatment arms included infections and neutropenia.

Full data of both Phase 2b trials will be submitted for presentation at an upcoming scientific conference.

About SarilumabSarilumab (REGN88/ SAR153191) is the first fully human monoclonal antibody directed against the alpha subunit of the IL-6 receptor complex (IL-6R alpha).  Sarilumab is a high affinity, sub-cutaneously delivered, specific inhibitor of IL-6 signaling.  It blocks the binding of IL-6 to its receptor and interrupts the resultant cyto
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
2. Sanofi Enters Into Research Collaboration with Weill Cornell Medical College to Discover New Treatments for Tuberculosis
3. Sanofi Pasteur Commends Winners of International BioGENEius Challenge
4. Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen
5. Medco, United BioSource and Sanofi Signed Global Agreement to Improve Quality of Patient Care Through Real-World Evidence
6. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
7. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims
8. sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
9. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
10. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
11. Sanofi-Aventis Completes Acquisition of Genzyme Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent pharmacy ... proud to announce its expansion into a new corporate headquarters ... feature an 8,000-square-foot office space and state of the art ... for 100 open positions for the new facility. ... Road will serve as the chain,s corporate headquarters and closed ...
(Date:8/20/2014)... 2014 Reportlinker.com announces ... in its catalogue: EMR 2014: The ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously ... (EMR) for nearly a decade, and each year ... Our report has become the industry standard, oft-quoted ...
(Date:8/19/2014)... , Aug. 19, 2014  The Alabama Supreme Court, ... patients can sue drug makers who mislead doctors into believing ... side‑effects.  The case is Weeks v. Wyeth, and the decision ... in that same case last year. Heninger Garrison Davis attorneys ... the patient in the case, Danny Weeks . ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4
... Corporation (NASDAQ: THOR ), a world leader ... and restore failing hearts, today announced that it will ... Wednesday, February 8. The company will hold ... operating activities, open to all interested parties, at 1:30 ...
... PuraMed BioScience, Inc. (OTCBB: PMBS) announced today that ... natural product for the treatment of migraine headaches, is ... Drug Chain in the United States. With the addition ... in approximately 15,000 stores nationwide. "We are ...
Cached Medicine Technology:Thoratec Schedules Fourth Quarter Conference Call, Webcast 2PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States 2
(Date:8/20/2014)... Botanica Day Spa has ... new and popular stem cell line from Pevonia®, ... wrinkles and naturally repairs the skin. The spa ... service by offering clients a complimentary dermaplaning session ... , Pevonia® continues to be a global leader ...
(Date:8/20/2014)... 2014 (HealthDay News) -- Leaving the car at home and ... good for your health, a new study indicates. Researchers ... found that 76 percent of men and 72 percent of ... percent of women used public transit, and 14 percent of ... Those who drove to work weighed more and had higher ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, ... blocks. , Urbini, a new collection of versatile baby gear ... jogger to its lineup. , The Avi has been ... by the latest racing styles and a set of features ... offers a swift, smooth ride on runs, power-walks and causal ...
(Date:8/20/2014)... D.C. (PRWEB) August 20, 2014 ... received a five-year, $1.24 million Science Education Partnership ... Health to support NAHN’s collaborative project with the ... in Health Careers. , This collaborative NIH R25 ... for cultural and linguistic diversity among health professionals ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... BUFFALO, N.Y. -- The University at Buffalo announced today a ... and family to establish the Jacobs Institute, which will support ... of heart and vascular diseases. , ... was made in honor of Lawrence D. Jacobs, M.D., a ...
... 13 Market competition is,mounting to win ... most highly,qualified clinical investigators. Companies that develop ... their studies win an advantage in,bringing their ... white paper "Recruiting and Retaining,High-Quality Clinical Investigators" ...
... for recent disasters, WASHINGTON, June 13 The ... with relief efforts for,the victims of flooding and tornadoes ... West Virginia, the Red Cross is present,with vast amounts ... of,thousands of meals., Already, more than 1,400 Red ...
... Long and costly product,development cycles make it essential ... to the development of compounds with,the greatest potential ... and earlier into the new product process in ... development cycle,time, focus resources for greatest impact and ...
... lead to diagnostic urine test for 10% of men with ... traits of an aggressive type of prostate cancer that occurs ... been identified in hopes of finding a way to diagnose ... the Michigan Center for Translational Pathology at the University of ...
... June 2008: The TRAF1/C5 locus on chromosome 9 has ... diseases including type 1 diabetes and systemic lupus erythematosus ... 2008, the Annual Congress of the European League Against ... Factor-receptor associated factor 1) and C5 (complement component 5) ...
Cached Medicine News:Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 2Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 3Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 4Health News:American Red Cross Issues Appeal for Disaster Relief Fund 2Health News:Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence 2Health News:Researchers ID Traits of Aggressive Prostate Cancer 2Health News:Specific location of the TRAF1/C5 gene associated with multiple autoimmune diseases 2
... AMO Prestige System marked an amazing ... of safety with high-performance fluidics.A.S.E.T. keeps ... conditions in the in the anterior ... the reaction and interaction of the ...
Highly versatile, efficient, compact and accurate digital readout display....
... system has all the features of phaco ... engineering means minimal maintenance. Small, light and ... to site. Lowest cost reusable tubing kit ... longer is there a price objection to ...
The CV-12000 provides the surgeon with all the options to perform today's newest techniques....
Medicine Products: